Stock A003000 BUKWANG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Bukwang Pharmaceutical Co., Ltd.

Equities

A003000

KR7003000007

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
6,150 KRW 0.00% Intraday chart for Bukwang Pharmaceutical Co., Ltd. +2.67% +0.82%
Apr. 01 H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion. CI
Mar. 26 Bukwang Pharmaceutical Shares Surge Following Buyback Program Announcement MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Bukwang Pharmaceutical Co., Ltd.

H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion. CI
Bukwang Pharmaceutical Shares Surge Following Buyback Program Announcement MT
H Delta Private Equity Partnership agreed to acquire 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion. CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Bukwang Pharmaceutical Co., Ltd.(KOSE:A003000) dropped from KOSPI 200 Index CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
OCI Company Ltd. completed the acquisition of additional 10.878134% stake in Bukwang Pharmaceutical Co., Ltd. (KOSE : A003000) from Kim Sanghun and 8 other shareholders for approximately KRW 150 billion. CI
OCI Company Ltd. agreed to acquire an additional 10.878134% stake in Bukwang Pharmaceutical Co., Ltd. (KOSE : A003000) from Kim Sanghun and 8 other shareholders for approximately KRW 150 billion. CI
ImmPACT Bio USA Inc. announced that it has received $110.855843 million in funding from a group of investors CI
ImmPACT Bio USA Inc. announced that it expects to receive $110.855843 million in funding CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
ImmPACT Bio USA Inc. announced that it has received $18.250003 million in funding from a group of investors CI
ImmPACT Bio USA Inc. announced that it expects to receive $20.000009 million in funding CI
Bukwang Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 8, 2020, has expired. CI
Bukwang Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 8, 2020, has expired. CI
Bukwang Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 8, 2020, has expired. CI
Bukwang Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,916,000 shares. CI
Bukwang Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Protekt Therapeutics Ltd announced that it expects to receive $3.6 million in funding from a group of investors CI

Chart Bukwang Pharmaceutical Co., Ltd.

Chart Bukwang Pharmaceutical Co., Ltd.
More charts

Company Profile

Bukwang Pharm Co Ltd is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-08-13 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
BUKWANG PHARMACEUTICAL CO., LTD. Stock Bukwang Pharmaceutical Co., Ltd.
+0.82% 306M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A003000 Stock
  4. News Bukwang Pharmaceutical Co., Ltd.
  5. Bukwang Pharmaceutical Shares Surge Following Buyback Program Announcement